ES2541364T3 - Péptido - Google Patents

Péptido Download PDF

Info

Publication number
ES2541364T3
ES2541364T3 ES10779020.6T ES10779020T ES2541364T3 ES 2541364 T3 ES2541364 T3 ES 2541364T3 ES 10779020 T ES10779020 T ES 10779020T ES 2541364 T3 ES2541364 T3 ES 2541364T3
Authority
ES
Spain
Prior art keywords
leu
pro
gln
phe
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10779020.6T
Other languages
English (en)
Inventor
Ganesh Chandramowli
Babu Rakesh Kumar Bandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2541364T3 publication Critical patent/ES2541364T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Péptido seleccionado de: (i) SEQ ID NO:1 es Xm-Leu-Ser-Arg-His-Val-Leu-Gln-Xn (Xm-LSRHVLQ-Xn); o (ii) SEQ ID NO:2 es Xm-His-Gly-His-Pro-Phe-Ala-Pro-Xn (Xm-HGHPFAP-Xn), en el que cada X se selecciona independientemente del grupo que consiste en Gly, Ala, Val, Leu, Ile, Ser, Thr, Phe, Tyr, Trp, Cys, Pro, His, Glu, Asp, Gln, Asn, Lys, Arg y Met, y m y n son cada uno independientemente un número entero desde 0 hasta 5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10779020.6T 2009-12-16 2010-11-23 Péptido Active ES2541364T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2898MU2009 2009-12-16
INMU28982009 2009-12-16
PCT/EP2010/067972 WO2011072991A1 (en) 2009-12-16 2010-11-23 Peptide

Publications (1)

Publication Number Publication Date
ES2541364T3 true ES2541364T3 (es) 2015-07-17

Family

ID=43533119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10779020.6T Active ES2541364T3 (es) 2009-12-16 2010-11-23 Péptido

Country Status (11)

Country Link
US (1) US8580920B2 (es)
EP (1) EP2512496B1 (es)
JP (1) JP5752145B2 (es)
CN (1) CN103313723B (es)
BR (1) BR112012013095A2 (es)
CA (1) CA2782131C (es)
EA (1) EA022214B1 (es)
ES (1) ES2541364T3 (es)
MX (1) MX2012007034A (es)
WO (1) WO2011072991A1 (es)
ZA (1) ZA201203722B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730429T3 (es) * 2013-10-18 2019-11-11 Univ Do Minho Composición peptídica y usos de la misma
US11712410B2 (en) 2018-09-05 2023-08-01 K18, Inc. Composition for improving hair health
TW202216111A (zh) 2020-07-03 2022-05-01 米尼奧大學 香氛釋放機制、方法及其用途
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389950A1 (en) * 1989-03-23 1990-10-03 Lion Corporation Melanocyte-stimulating hormone inhibitor and external preparation containing the same
GB9719195D0 (en) * 1997-09-09 1997-11-12 Unilever Plc Skin lightening composition
WO2001088088A2 (en) * 2000-05-18 2001-11-22 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2001002527A (ja) 1999-06-22 2001-01-09 Lion Corp 皮膚外用剤組成物
US20070060743A1 (en) * 2001-05-16 2007-03-15 Tang Y Tom Novel nucleic acids and polypeptides
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
CA2644273A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
FR2900573B1 (fr) * 2006-05-05 2014-05-16 Sederma Sa Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema

Also Published As

Publication number Publication date
JP5752145B2 (ja) 2015-07-22
CN103313723B (zh) 2015-02-04
MX2012007034A (es) 2012-07-04
WO2011072991A1 (en) 2011-06-23
US20120263665A1 (en) 2012-10-18
CA2782131A1 (en) 2011-06-23
BR112012013095A2 (pt) 2017-05-16
ZA201203722B (en) 2013-08-28
EP2512496A1 (en) 2012-10-24
EP2512496B1 (en) 2015-04-01
CA2782131C (en) 2018-12-11
EA022214B1 (ru) 2015-11-30
CN103313723A (zh) 2013-09-18
US8580920B2 (en) 2013-11-12
EA201200889A1 (ru) 2013-01-30
JP2013514291A (ja) 2013-04-25

Similar Documents

Publication Publication Date Title
AR124918A2 (es) Proteínas insecticidas nuevas y métodos de uso
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
ES2541364T3 (es) Péptido
RU2014138499A (ru) АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FycRIIB
AR058888A1 (es) Formulaciones estabilizadas que contienen anticuerpos
Takagi et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
ME03709B (me) Fuzijski proteini
RU2010116278A (ru) Модифицированная константная область антитела
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
NZ600732A (en) Oxyntomodulin peptide analogue
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NZ609216A (en) Anticancer fusion protein
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
CA2839298C (en) Anti-inflammatory pharmaceutical products
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E